Cystatin C: Which Tests to Order Alongside for a Complete Kidney Picture

What Cystatin C Actually Measures

Cystatin C is a 13-kDa protein produced at a near-constant rate by all nucleated cells in the body, filtered freely by the glomerulus, and then reabsorbed and catabolized in the proximal tubule. Because its production does not depend on muscle mass the way creatinine does, it offers a less biased window into glomerular filtration rate (GFR). The 2012 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) analysis (N=5,352) demonstrated that combining cystatin C with creatinine improved GFR estimation accuracy over either marker alone, reclassifying 19% of participants into more appropriate risk categories 1.

A single cystatin C value, though, cannot distinguish between a filtering problem and a downstream injury like tubular proteinuria. It does not tell you whether kidney damage is acute or chronic. And it can be thrown off by thyroid dysfunction, high-dose corticosteroids, or active inflammation. That is why pairing it with complementary tests matters.

The 2021 race-free CKD-EPI equation, endorsed by the National Kidney Foundation and the American Society of Nephrology, uses both serum creatinine and cystatin C to produce a single eGFR without a race coefficient 2. This equation is now the recommended default for laboratories across the United States.

Test 1: Serum Creatinine (the Essential Partner)

Every cystatin C order should include serum creatinine. The reason is mathematical: the 2021 CKD-EPI creatinine-cystatin C equation requires both analytes. Using creatinine alone can overestimate kidney function in people with low muscle mass (older adults, those on GLP-1 receptor agonists losing lean tissue, amputees) and underestimate it in highly muscular individuals. A 2022 meta-analysis in the American Journal of Kidney Diseases (32 studies, N=87,281) found that the combined equation reduced misclassification of CKD stage by 23% compared with creatinine-only eGFR 3.

When you order both markers simultaneously, your lab report should auto-calculate eGFR from each equation (creatinine-only, cystatin C-only, and combined). If your lab does not auto-report the combined eGFR, you can plug both values into the NKF's online calculator at kidney.org.

Dr. Andrew Levey, the lead author of the CKD-EPI equations, has stated: "The creatinine-cystatin C equation should be the preferred confirmatory test whenever GFR estimation influences clinical decisions" 2.

Test 2: Urine Albumin-to-Creatinine Ratio (UACR)

GFR and albuminuria are the two independent axes of CKD staging in the KDIGO 2024 guidelines 4. You cannot stage kidney disease accurately without both. A spot UACR on a first-morning void is the practical standard. Normal is below 30 mg/g. Moderately increased albuminuria (30 to 300 mg/g) signals early glomerular or tubular injury, often years before GFR drops.

This matters clinically. A patient with an eGFR of 55 mL/min/1.73 m² and a UACR of 250 mg/g has a vastly different five-year prognosis than one with the same eGFR and a UACR of 10 mg/g. The KDIGO heat map assigns the first patient to "high risk" and the second to "moderately increased risk."

In people taking SGLT2 inhibitors or finerenone for diabetic kidney disease, serial UACR also serves as a treatment-response marker. A 30% or greater reduction in UACR within three months of starting dapagliflozin predicted long-term renal benefit in the DAPA-CKD trial (N=4,304) 5.

Test 3: Comprehensive Metabolic Panel (CMP)

A CMP bundles 14 analytes, including BUN, glucose, electrolytes (sodium, potassium, chloride, CO₂), calcium, total protein, albumin, and liver enzymes. Several of these directly contextualize a cystatin C result.

BUN-to-creatinine ratio helps differentiate prerenal azotemia (dehydration, heart failure) from intrinsic kidney disease. Serum bicarbonate (CO₂) flags metabolic acidosis, a complication of CKD stage 3b and beyond that accelerates progression if untreated. Potassium tracks hyperkalemia risk, especially relevant when prescribing ACE inhibitors, ARBs, or finerenone. Serum albumin below 3.5 g/dL may indicate nephrotic-range proteinuria or malnutrition.

Ordering a CMP alongside cystatin C and UACR gives you a single-draw kidney assessment panel: filtration (eGFR from two markers), damage (UACR), and systemic consequences (electrolytes, acid-base, nutritional status).

Test 4: Hemoglobin A1c or Fasting Glucose

Diabetes is the leading cause of CKD in the United States, responsible for approximately 44% of new end-stage kidney disease cases according to the United States Renal Data System 2023 annual report 6. If cystatin C is being drawn as part of a kidney health screen, checking glycemic status is a logical add-on. The American Diabetes Association's 2024 Standards of Care recommends annual eGFR and UACR testing for all patients with type 2 diabetes starting at diagnosis 7.

For patients already diagnosed with diabetes, a concurrent A1c clarifies whether glycemic control is contributing to declining GFR. For undiagnosed patients, finding an A1c of 6.5% or higher alongside a low cystatin C-based eGFR changes the clinical pathway entirely.

Test 5: Lipid Panel

CKD and cardiovascular disease share bidirectional risk. The 2013 ACC/AHA guidelines and the 2023 KDIGO lipid management update both treat eGFR below 60 mL/min/1.73 m² as a cardiovascular risk enhancer 8. A concurrent lipid panel (total cholesterol, LDL, HDL, triglycerides) helps determine statin candidacy.

In the SHARP trial (N=9,270), simvastatin plus ezetimibe reduced major atherosclerotic events by 17% in patients with CKD, with consistent benefit across eGFR subgroups 9. If you are drawing cystatin C to detect or stage kidney disease, a lipid panel drawn at the same visit avoids a second venipuncture and expedites cardiovascular risk stratification.

When to Add a Thyroid Panel

Cystatin C production rises in hyperthyroidism and drops in hypothyroidism, independent of kidney function. A 2014 study in Thyroid (N=1,572) found that TSH below 0.4 mIU/L was associated with a 12% higher cystatin C level after adjusting for measured GFR 10. If a patient's cystatin C-based eGFR is unexpectedly low but creatinine-based eGFR is normal, thyroid function should be checked before attributing the discrepancy to kidney disease.

This is one of the few situations where cystatin C can mislead. A free T4 and TSH drawn at the same time resolve the ambiguity.

Normal Cystatin C Range and How to Interpret Results

Most U.S. reference laboratories report a normal adult cystatin C range of 0.56 to 0.98 mg/L. Values above 1.0 mg/L generally correspond to an eGFR below 60 mL/min/1.73 m², though the relationship is nonlinear.

Cystatin C rises with age, just as GFR declines. A 0.95 mg/L reading in a 75-year-old means something different than the same number in a 30-year-old. The combined CKD-EPI equation accounts for age, so always interpret cystatin C through the lens of the calculated eGFR rather than as a standalone number.

Mild elevations (0.99 to 1.15 mg/L) with a normal creatinine may represent early stage 2 CKD that creatinine alone would miss. The Prevention of Renal and Vascular End-stage Disease (PREVEND) study (N=8,058) found that cystatin C detected GFR decline an average of 3.2 years earlier than creatinine in a general-population cohort 11.

How to Lower Cystatin C

Because cystatin C is a filtration marker, lowering it means improving glomerular filtration. The interventions that matter are the same ones that slow CKD progression.

Blood pressure control to a target below 130/80 mmHg reduced composite kidney endpoints by 19% in the SPRINT trial (N=9,361, median follow-up 3.3 years) 12. SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) slow eGFR decline across diabetic and non-diabetic CKD populations. In the EMPA-KIDNEY trial (N=6,609), empagliflozin reduced progression of kidney disease by 28% versus placebo 13.

Dr. Hiddo Lambers Heerspink, the principal investigator of the DAPA-CKD trial, has noted: "SGLT2 inhibitors now represent a standard of care for CKD patients with eGFR 20 to 45, regardless of diabetes status" 5.

Weight management helps as well. Obesity-related hyperfiltration precedes CKD. Semaglutide 2.4 mg in the FLOW trial (N=3,533) reduced the risk of clinically significant kidney outcomes by 24% in patients with type 2 diabetes and CKD 14. Protein restriction to 0.6 to 0.8 g/kg/day may slow progression in stage 3b and beyond, though adherence is challenging and the evidence base is modest.

Smoking cessation, limiting NSAID use, and avoiding nephrotoxic contrast dye exposure round out the modifiable-risk list.

What a High Cystatin C Means

A cystatin C above 1.0 mg/L typically corresponds to reduced kidney filtration. But context determines urgency. An isolated elevation in a patient with uncontrolled hyperthyroidism, high-dose prednisone use, or active systemic inflammation (CRP above 10 mg/L) may not reflect true GFR decline. Rule these confounders out before diagnosing CKD.

If the combined eGFR from creatinine and cystatin C is below 60 mL/min/1.73 m² on two measurements separated by at least 90 days, the KDIGO criteria for CKD are met 4. At that point, the clinical pathway shifts to cause identification (renal ultrasound, autoimmune serologies if indicated), risk stratification (UACR category, KDIGO heat map), and nephrology referral for eGFR below 30 or rapidly declining trajectories.

Acute kidney injury (AKI) also raises cystatin C, often faster than creatinine. A 2011 Lancet study (N=444) showed cystatin C detected AKI 1 to 2 days earlier than creatinine in post-cardiac-surgery patients 15.

What a Low Cystatin C Means

A cystatin C below 0.55 mg/L is uncommon and generally reflects hyperfiltration (eGFR above 120 mL/min/1.73 m²) or very low production due to hypothyroidism. Hyperfiltration occurs in early diabetes, obesity, pregnancy, and high-protein diets. It is not benign. Sustained hyperfiltration precedes glomerular injury and eventual GFR decline. In a prospective cohort from the Chronic Renal Insufficiency Cohort (CRIC) study (N=3,939), baseline hyperfiltration was associated with a 40% higher risk of reaching the composite kidney outcome over a median 7.9-year follow-up 16.

If cystatin C is very low and TSH is elevated (above 4.5 mIU/L), treat the thyroid disorder first and repeat the test.

The Optimal Order Set: Putting It All Together

For a first-time cystatin C evaluation, order these tests from a single fasting blood draw plus a spot urine:

1. Cystatin C
2. Serum creatinine (with auto-calculated eGFR from both the creatinine-only and combined equations)
3. Comprehensive metabolic panel (BUN, electrolytes, glucose, albumin, liver enzymes, calcium)
4. Urine albumin-to-creatinine ratio (spot, first-morning void preferred)
5. Hemoglobin A1c
6. Lipid panel
7. TSH (if cystatin C and creatinine eGFRs diverge, or if thyroid disease is suspected)

This set covers filtration, damage, metabolic consequences, and the three most common drivers of CKD (diabetes, hypertension, dyslipidemia). Total out-of-pocket cost for an uninsured patient at a direct-access lab runs approximately $150 to $250 for the full panel.

For follow-up monitoring in a patient with established CKD, the minimum repeat set is cystatin C, creatinine, CMP, and UACR every 3 to 12 months depending on stage and trajectory per KDIGO 2024 recommendations 4.